Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics.

Pas T, Verbert S, Appeltans B, Van den Mooter G.

Int J Pharm. 2019 Nov 28:118884. doi: 10.1016/j.ijpharm.2019.118884. [Epub ahead of print]

PMID:
31786356
2.

Solid-state analysis of amorphous solid dispersions: Why DSC and XRPD may not be regarded as stand-alone techniques.

Dedroog S, Pas T, Vergauwen B, Huygens C, Van den Mooter G.

J Pharm Biomed Anal. 2019 Oct 18:112937. doi: 10.1016/j.jpba.2019.112937. [Epub ahead of print]

PMID:
31679845
3.

Myth or Truth: The Glass Forming Ability Class III Drugs Will Always Form Single-Phase Homogenous Amorphous Solid Dispersion Formulations.

Panini P, Rampazzo M, Singh A, Vanhoutte F, Van den Mooter G.

Pharmaceutics. 2019 Oct 14;11(10). pii: E529. doi: 10.3390/pharmaceutics11100529.

4.

Tracking solid state dynamics in spray-dried protein powders at infrared and terahertz frequencies.

Shmool TA, Batens M, Massant J, Van den Mooter G, Zeitler JA.

Eur J Pharm Biopharm. 2019 Nov;144:244-251. doi: 10.1016/j.ejpb.2019.09.013. Epub 2019 Sep 20. No abstract available.

PMID:
31546022
5.

Comparative study of the potential of poly(2-ethyl-2-oxazoline) as carrier in the formulation of amorphous solid dispersions of poorly soluble drugs.

Boel E, Smeets A, Vergaelen M, De la Rosa VR, Hoogenboom R, Van den Mooter G.

Eur J Pharm Biopharm. 2019 Nov;144:79-90. doi: 10.1016/j.ejpb.2019.09.005. Epub 2019 Sep 6.

PMID:
31499162
6.
7.

Drug-carrier binding and enzymatic carrier digestion in amorphous solid dispersions containing proteins as carrier.

Pas T, Bergonzi A, Lescrinier E, Vergauwen B, Van den Mooter G.

Int J Pharm. 2019 May 30;563:358-372. doi: 10.1016/j.ijpharm.2019.03.062. Epub 2019 Mar 29.

PMID:
30935916
8.

Size Analysis of Small Particles in Wet Dispersions by Laser Diffractometry: A Guidance to Quality Data.

De Cleyn E, Holm R, Van den Mooter G.

J Pharm Sci. 2019 May;108(5):1905-1914. doi: 10.1016/j.xphs.2018.12.010. Epub 2018 Dec 19.

PMID:
30578802
9.

Chemically identical but physically different: A comparison of spray drying, hot melt extrusion and cryo-milling for the formulation of high drug loaded amorphous solid dispersions of naproxen.

Dedroog S, Huygens C, Van den Mooter G.

Eur J Pharm Biopharm. 2019 Feb;135:1-12. doi: 10.1016/j.ejpb.2018.12.002. Epub 2018 Dec 5.

PMID:
30529295
10.

Ability of gelatin and BSA to stabilize the supersaturated state of poorly soluble drugs.

Pas T, Struyf A, Vergauwen B, Van den Mooter G.

Eur J Pharm Biopharm. 2018 Oct;131:211-223. doi: 10.1016/j.ejpb.2018.08.003. Epub 2018 Aug 17.

PMID:
30121247
11.

Amorphous solid dispersions of darunavir: Comparison between spray drying and electrospraying.

Smeets A, Koekoekx R, Clasen C, Van den Mooter G.

Eur J Pharm Biopharm. 2018 Sep;130:96-107. doi: 10.1016/j.ejpb.2018.06.021. Epub 2018 Jun 19.

PMID:
29928980
12.

Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls.

Batens M, Massant J, Teodorescu B, Van den Mooter G.

Eur J Pharm Biopharm. 2018 Jun;127:407-422. doi: 10.1016/j.ejpb.2018.02.002. Epub 2018 Feb 27.

PMID:
29499299
13.

Microstructure of Pharmaceutical Semicrystalline Dispersions: The Significance of Polymer Conformation.

Van Duong T, Goderis B, Van Humbeeck J, Van den Mooter G.

Mol Pharm. 2018 Feb 5;15(2):629-641. doi: 10.1021/acs.molpharmaceut.7b01007. Epub 2018 Jan 24.

PMID:
29320195
14.

Polymorphism of Indomethacin in Semicrystalline Dispersions: Formation, Transformation, and Segregation.

Van Duong T, Lüdeker D, Van Bockstal PJ, De Beer T, Van Humbeeck J, Van den Mooter G.

Mol Pharm. 2018 Mar 5;15(3):1037-1051. doi: 10.1021/acs.molpharmaceut.7b00930. Epub 2018 Jan 29.

PMID:
29307188
15.

Exploring the feasibility of the use of biopolymers as a carrier in the formulation of amorphous solid dispersions - Part I: Gelatin.

Pas T, Vergauwen B, Van den Mooter G.

Int J Pharm. 2018 Jan 15;535(1-2):47-58. doi: 10.1016/j.ijpharm.2017.10.050. Epub 2017 Oct 31.

PMID:
29097142
16.

The impact of guest compounds on cyclodextrin aggregation behavior: A series of structurally related parabens.

Stappaerts J, Do Thi T, Dominguez-Vega E, Somsen GW, Van den Mooter G, Augustijns P.

Int J Pharm. 2017 Aug 30;529(1-2):442-450. doi: 10.1016/j.ijpharm.2017.07.026. Epub 2017 Jul 10.

PMID:
28705618
17.

Electrospraying of polymer solutions: Study of formulation and process parameters.

Smeets A, Clasen C, Van den Mooter G.

Eur J Pharm Biopharm. 2017 Oct;119:114-124. doi: 10.1016/j.ejpb.2017.06.010. Epub 2017 Jun 10.

PMID:
28610878
18.

Thermodynamic Study of the Interaction of Bovine Serum Albumin and Amino Acids with Cellulose Nanocrystals.

Lombardo S, Eyley S, Schütz C, van Gorp H, Rosenfeldt S, Van den Mooter G, Thielemans W.

Langmuir. 2017 Jun 6;33(22):5473-5481. doi: 10.1021/acs.langmuir.7b00710. Epub 2017 May 24.

19.

Indomethacin-containing interpolyelectrolyte complexes based on Eudragit® E PO/S 100 copolymers as a novel drug delivery system.

Moustafine RI, Sitenkov AY, Bukhovets AV, Nasibullin SF, Appeltans B, Kabanova TV, Khutoryanskiy VV, Van den Mooter G.

Int J Pharm. 2017 May 30;524(1-2):121-133. doi: 10.1016/j.ijpharm.2017.03.053. Epub 2017 Mar 31.

PMID:
28366803
20.

Spectroscopic Investigation of the Formation and Disruption of Hydrogen Bonds in Pharmaceutical Semicrystalline Dispersions.

Van Duong T, Reekmans G, Venkatesham A, Van Aerschot A, Adriaensens P, Van Humbeeck J, Van den Mooter G.

Mol Pharm. 2017 May 1;14(5):1726-1741. doi: 10.1021/acs.molpharmaceut.6b01172. Epub 2017 Apr 11.

PMID:
28363028
21.

A study of the aggregation of cyclodextrins: Determination of the critical aggregation concentration, size of aggregates and thermodynamics using isodesmic and K2-K models.

Do TT, Van Hooghten R, Van den Mooter G.

Int J Pharm. 2017 Apr 15;521(1-2):318-326. doi: 10.1016/j.ijpharm.2017.02.037. Epub 2017 Feb 17.

PMID:
28216462
22.

Controlling the Release of Indomethacin from Glass Solutions Layered with a Rate Controlling Membrane Using Fluid-Bed Processing. Part 2: The Influence of Formulation Parameters on Drug Release.

Dereymaker A, Pelgrims J, Engelen F, Adriaensens P, Van den Mooter G.

Mol Pharm. 2017 Apr 3;14(4):974-983. doi: 10.1021/acs.molpharmaceut.6b01024. Epub 2017 Feb 28.

PMID:
28207272
23.

Controlling the Release of Indomethacin from Glass Solutions Layered with a Rate Controlling Membrane Using Fluid-Bed Processing. Part 1: Surface and Cross-Sectional Chemical Analysis.

Dereymaker A, Scurr DJ, Steer ED, Roberts CJ, Van den Mooter G.

Mol Pharm. 2017 Apr 3;14(4):959-973. doi: 10.1021/acs.molpharmaceut.6b01023. Epub 2017 Feb 28.

PMID:
28206770
24.

Eudragit® RL as a stabilizer for supersaturation and a substrate for nanocrystal formation.

Dereymaker A, Cinghia G, Van den Mooter G.

Eur J Pharm Biopharm. 2017 May;114:250-262. doi: 10.1016/j.ejpb.2017.02.002. Epub 2017 Feb 9.

PMID:
28189622
25.

Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters.

Riekes MK, Dereymaker A, Berben P, Augustijns P, Stulzer HK, Van den Mooter G.

Int J Pharm. 2017 Mar 30;520(1-2):49-58. doi: 10.1016/j.ijpharm.2017.01.053. Epub 2017 Jan 30.

PMID:
28153650
26.

Encapsulating darunavir nanocrystals within Eudragit L100 using coaxial electrospraying.

Nguyen DN, Clasen C, Van den Mooter G.

Eur J Pharm Biopharm. 2017 Apr;113:50-59. doi: 10.1016/j.ejpb.2016.12.002. Epub 2016 Dec 16.

PMID:
27993734
27.

Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: Proof of concept in man.

Bukara K, Schueller L, Rosier J, Martens MA, Daems T, Verheyden L, Eelen S, Van Speybroeck M, Libanati C, Martens JA, Van Den Mooter G, Frérart F, Jolling K, De Gieter M, Bugarski B, Kiekens F.

Eur J Pharm Biopharm. 2016 Nov;108:220-225. doi: 10.1016/j.ejpb.2016.08.020. Epub 2016 Sep 17.

PMID:
27648957
28.

Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study.

Boets E, Gomand SV, Deroover L, Preston T, Vermeulen K, De Preter V, Hamer HM, Van den Mooter G, De Vuyst L, Courtin CM, Annaert P, Delcour JA, Verbeke KA.

J Physiol. 2017 Jan 15;595(2):541-555. doi: 10.1113/JP272613. Epub 2016 Sep 18.

29.

In Vivo Performance of Fenofibrate Formulated With Ordered Mesoporous Silica Versus 2-Marketed Formulations: A Comparative Bioavailability Study in Beagle Dogs.

Bukara K, Schueller L, Rosier J, Daems T, Verheyden L, Eelen S, Martens JA, Van den Mooter G, Bugarski B, Kiekens F.

J Pharm Sci. 2016 Aug;105(8):2381-5. doi: 10.1016/j.xphs.2016.05.019. Epub 2016 Jun 28.

PMID:
27364460
30.

The role of the carrier in the formulation of pharmaceutical solid dispersions. Part I: crystalline and semi-crystalline carriers.

Van Duong T, Van den Mooter G.

Expert Opin Drug Deliv. 2016 Nov;13(11):1583-1594. Epub 2016 Jun 20. Review.

PMID:
27321133
31.

Pharmaceutical Applications of Electrospraying.

Nguyen DN, Clasen C, Van den Mooter G.

J Pharm Sci. 2016 Sep;105(9):2601-2620. doi: 10.1016/j.xphs.2016.04.024. Epub 2016 Jun 7. Review.

PMID:
27287515
32.

The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers.

Van Duong T, Van den Mooter G.

Expert Opin Drug Deliv. 2016 Dec;13(12):1681-1694. Epub 2016 Jun 17. Review.

PMID:
27267583
33.

Drug loaded and ethylcellulose coated mesoporous silica for controlled drug release prepared using a pilot scale fluid bed system.

Hacene YC, Singh A, Van den Mooter G.

Int J Pharm. 2016 Jun 15;506(1-2):138-47. doi: 10.1016/j.ijpharm.2016.04.047. Epub 2016 Apr 20.

PMID:
27107901
34.

Effect of Compression on the Molecular Arrangement of Itraconazole-Soluplus Solid Dispersions: Induction of Liquid Crystals or Exacerbation of Phase Separation?

Singh A, Bharati A, Frederiks P, Verkinderen O, Goderis B, Cardinaels R, Moldenaers P, Van Humbeeck J, Van den Mooter G.

Mol Pharm. 2016 Jun 6;13(6):1879-93. doi: 10.1021/acs.molpharmaceut.6b00046. Epub 2016 May 4.

PMID:
27092396
35.

The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.

Darville N, van Heerden M, Mariën D, De Meulder M, Rossenu S, Vermeulen A, Vynckier A, De Jonghe S, Sterkens P, Annaert P, Van den Mooter G.

J Control Release. 2016 May 28;230:95-108. doi: 10.1016/j.jconrel.2016.03.041. Epub 2016 Apr 9.

PMID:
27067365
36.

Self-Assembly of Cyclodextrins and Their Complexes in Aqueous Solutions.

Ryzhakov A, Do Thi T, Stappaerts J, Bertoletti L, Kimpe K, Sá Couto AR, Saokham P, Van den Mooter G, Augustijns P, Somsen GW, Kurkov S, Inghelbrecht S, Arien A, Jimidar MI, Schrijnemakers K, Loftsson T.

J Pharm Sci. 2016 Sep;105(9):2556-2569. doi: 10.1016/j.xphs.2016.01.019. Epub 2016 Mar 12. Review.

PMID:
26975246
37.

New Perspectives for Fixed Dose Combinations of Poorly Water-Soluble Compounds: a Case Study with Ezetimibe and Lovastatin.

Riekes MK, Engelen A, Appeltans B, Rombaut P, Stulzer HK, Van den Mooter G.

Pharm Res. 2016 May;33(5):1259-75. doi: 10.1007/s11095-016-1870-z. Epub 2016 Feb 8.

PMID:
26857899
38.

Spray drying formulation of amorphous solid dispersions.

Singh A, Van den Mooter G.

Adv Drug Deliv Rev. 2016 May 1;100:27-50. doi: 10.1016/j.addr.2015.12.010. Epub 2015 Dec 17. Review.

PMID:
26705850
39.

Modeling the Time Course of the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate Nano-/Microcrystals and Polystyrene Microspheres in the Rat.

Darville N, van Heerden M, Erkens T, De Jonghe S, Vynckier A, De Meulder M, Vermeulen A, Sterkens P, Annaert P, Van den Mooter G.

Toxicol Pathol. 2016 Feb;44(2):189-210. doi: 10.1177/0192623315618291. Epub 2015 Dec 23.

PMID:
26698322
40.

Compression Effects on the Phase Behaviour of Miconazole-Poly (1-Vinylpyrrolidone-Co-Vinyl Acetate) Solid Dispersions-Role of Pressure, Dwell Time, and Preparation Method.

Singh A, De Bisschop C, Schut H, Van Humbeeck J, Van Den Mooter G.

J Pharm Sci. 2015 Oct;104(10):3366-76. doi: 10.1002/jps.24540. Epub 2015 Jun 17.

PMID:
26351161
41.

Multimodal non-linear optical imaging for the investigation of drug nano-/microcrystal-cell interactions.

Darville N, Saarinen J, Isomäki A, Khriachtchev L, Cleeren D, Sterkens P, van Heerden M, Annaert P, Peltonen L, Santos HA, Strachan CJ, Van den Mooter G.

Eur J Pharm Biopharm. 2015 Oct;96:338-48. doi: 10.1016/j.ejpb.2015.09.003. Epub 2015 Sep 5.

PMID:
26347923
42.

Characterization of the Sublimation and Vapor Pressure of 2-(2-Nitrovinyl) Furan (G-0) Using Thermogravimetric Analysis: Effects of Complexation with Cyclodextrins.

Ruz V, González MM, Winant D, Rodríguez Z, Van den Mooter G.

Molecules. 2015 Aug 19;20(8):15175-91. doi: 10.3390/molecules200815175.

43.

One-step production of darunavir solid dispersion nanoparticles coated with enteric polymers using electrospraying.

Nguyen DN, Palangetic L, Clasen C, Van den Mooter G.

J Pharm Pharmacol. 2016 May;68(5):625-33. doi: 10.1111/jphp.12459. Epub 2015 Aug 14.

PMID:
26272245
44.

CO₂ controlled flocculation of microalgae using pH responsive cellulose nanocrystals.

Eyley S, Vandamme D, Lama S, Van den Mooter G, Muylaert K, Thielemans W.

Nanoscale. 2015 Sep 14;7(34):14413-21. doi: 10.1039/c5nr03853g.

PMID:
26248574
45.

Highly charged cellulose-based nanocrystals as flocculants for harvesting Chlorella vulgaris.

Vandamme D, Eyley S, Van den Mooter G, Muylaert K, Thielemans W.

Bioresour Technol. 2015 Oct;194:270-5. doi: 10.1016/j.biortech.2015.07.039. Epub 2015 Jul 17.

PMID:
26210139
46.

Visualization of delayed release of compounds from pH-sensitive capsules in vitro and in vivo in a hamster model.

Staelens D, Liang S, Appeltans B, Van de Wouwer M, Van den Mooter G, Van Assche G, Himmelreich U, Vande Velde G.

Contrast Media Mol Imaging. 2016 Jan-Feb;11(1):24-31. doi: 10.1002/cmmi.1654. Epub 2015 Jul 20.

PMID:
26190202
47.

Crystallization Kinetics of Indomethacin/Polyethylene Glycol Dispersions Containing High Drug Loadings.

Duong TV, Van Humbeeck J, Van den Mooter G.

Mol Pharm. 2015 Jul 6;12(7):2493-504. doi: 10.1021/acs.molpharmaceut.5b00299. Epub 2015 Jun 19.

PMID:
26056715
48.

The peculiar behavior of the glass transition temperature of amorphous drug-polymer films coated on inert sugar spheres.

Dereymaker A, Van Den Mooter G.

J Pharm Sci. 2015 May;104(5):1759-66. doi: 10.1002/jps.24395. Epub 2015 Feb 20.

PMID:
25702912
49.

The influence of spray-drying parameters on phase behavior, drug distribution, and in vitro release of injectable microspheres for sustained release.

Meeus J, Lenaerts M, Scurr DJ, Amssoms K, Davies MC, Roberts CJ, Van Den Mooter G.

J Pharm Sci. 2015 Apr;104(4):1451-60. doi: 10.1002/jps.24361. Epub 2015 Feb 3.

PMID:
25648704
50.

In vivo evaluation of different formulation strategies for sustained release injectables of a poorly soluble HIV protease inhibitor.

Meeus J, Scurr DJ, Amssoms K, Wuyts K, Annaert P, Davies MC, Roberts CJ, Van den Mooter G.

J Control Release. 2015 Feb 10;199:1-9. doi: 10.1016/j.jconrel.2014.11.020. Epub 2014 Dec 6.

PMID:
25485732

Supplemental Content

Loading ...
Support Center